Hospital
Ahs Hillcrest Medical Center, LLC
Ahs Hillcrest Medical Center, LLC was paid $14.37M by Medicaid between Jan 2018 and Dec 2024, across 74 billing codes. Its largest line is 99285, emergency room visit (most serious) — 38% of everything it billed.
33Billing provider infoAHS HILLCREST MEDICAL CENTER, LLC
TULSA, OK 74104
TULSA, OK 74104
33aNPI1629057229assigned 01/11/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$14.37M
24GClaims167,561
24DCodes billed74
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Oklahoma
Rank by total paid#10 of 75
Median peer was paid$3.66M
This provider vs. median3.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 20,311 | $1.69M | |
| 2019 | 17,913 | $1.39M | |
| 2020 | 17,917 | $1.43M | |
| 2021 | 20,179 | $1.53M | |
| 2022 | 32,835 | $2.89M | |
| 2023 | 40,387 | $3.79M | |
| 2024incomplete | 18,019 | $1.65M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 38% | 16,784 | 16,421 | $5.43M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 28% | 17,134 | 16,841 | $4.06M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 14,701 | 14,210 | $2.27M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 5.7% | 6,430 | 6,308 | $827K |
| D9999 | Unspecified adjunctive procedure, by report | 3.5% | 495 | 494 | $501K |
| 80053 | Comprehensive metabolic panel | 1.2% | 18,054 | 16,786 | $167K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 21,312 | 19,368 | $143K |
| 36415 | Collection of venous blood by venipuncture | <1% | 23,773 | 21,303 | $137K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,674 | 2,534 | $108K |
| 71045 | Radiologic examination, chest; single view | <1% | 6,818 | 6,632 | $86K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 835 | 835 | $72K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 9,848 | 9,369 | $61K |
62 more codes
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,943 | $57K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 310 | $52K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 186 | $42K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 296 | $41K |
| 84484 | <1% | 2,950 | $37K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 206 | $31K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 76 | $27K |
| 95811 | <1% | 82 | $25K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 425 | $22K |
| 81002 | <1% | 6,139 | $20K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 435 | $16K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 152 | $15K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 520 | $11K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 208 | $10K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 39 | $10K |
| 83880 | <1% | 307 | $10K | |
| 81001 | <1% | 3,180 | $10K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 139 | $9K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,203 | $9K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 149 | $8K |
| 81025 | <1% | 1,088 | $8K | |
| 83690 | <1% | 1,232 | $7K | |
| 43235 | <1% | 12 | $6K | |
| 76801 | <1% | 79 | $5K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 95 | $5K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 52 | $5K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 36 | $4K |
| 83735 | <1% | 376 | $2K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 283 | $2K |
| 86850 | <1% | 265 | $2K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 52 | $2K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 52 | $2K |
| 84702 | <1% | 118 | $2K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 22 | $1K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 17 | $867.81 |
| 83605 | <1% | 65 | $812.91 | |
| 86900 | <1% | 292 | $795.69 | |
| 86901 | <1% | 278 | $752.42 | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 35 | $549.00 |
| 87210 | <1% | 93 | $434.49 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 28 | $411.60 |
| 82962 | <1% | 136 | $396.96 | |
| 82803 | <1% | 12 | $324.66 | |
| 87040 | <1% | 17 | $293.76 | |
| 97597 | <1% | 33 | $291.70 | |
| 81003 | <1% | 136 | $254.14 | |
| 82553 | <1% | 14 | $211.14 | |
| 87807 | <1% | 16 | $186.40 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 151 | $140.70 |
| 82550 | <1% | 14 | $118.98 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,343 | $89.10 |
| 87081 | <1% | 13 | $72.70 | |
| 84550 | <1% | 12 | $55.08 | |
| 82247 | <1% | 12 | $53.64 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 526 | $53.08 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 687 | $1.34 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 287 | $0.27 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 1,056 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 596 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 94 | $0.00 |
| 96376 | 0% | 21 | $0.00 | |
| 36416 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDOBBS, STEVE (CEO)
| Provider | Location | Paid |
|---|---|---|
| Secure Transportation Company, INC | Cerritos, CA | $53.78M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.